Triple Agonist Retatrutide Shows Superior Kidney Protection in Diabetic Mice

Diabetic Kidney Disease (DKD) is a severe microvascular complication of diabetes, affecting a significant portion of patients and often progressing to end-stage renal disease. Current treatments primarily focus on glycemic and blood pressure control, but there's a critical need for therapies that directly target the complex pathophysiology of DKD. This study aimed to directly compare the renoprotective effects of Liraglutide, Tirzepatide, and Retatrutide, a new generation of incretin-based therapies, in a robust animal model of diabetes.

The study revealed significant renoprotective effects across all three treatments, with notable differences in efficacy. Retatrutide, the triple GLP-1/GIP/GCGR agonist, demonstrated the most pronounced improvements. Albuminuria, a key indicator of kidney damage, was reduced by 62% in the Retatrutide group, 48% in the Tirzepatide group, and 27% in the Liraglutide group compared to controls (p<0.001 for all vs. control). Serum creatinine levels were significantly lower in the Retatrutide group (0.35 ± 0.02 mg/dL) compared to Tirzepatide (0.41 ± 0.03 mg/dL) and Liraglutide (0.52 ± 0.04 mg/dL), indicating better preserved renal function. Retatrutide significantly outperformed both Tirzepatide and Liraglutide in mitigating key markers of diabetic kidney disease progression, including albuminuria and renal fibrosis, achieving a 2.5-fold greater reduction in kidney inflammation compared to Liraglutide. Histological analysis showed a 55% reduction in glomerular hypertrophy and a 40% decrease in tubulointerstitial fibrosis in the Retatrutide group (p<0.01), superior to the 30% and 25% reductions observed with Tirzepatide, respectively. Inflammatory cytokine expression (e.g., TNF-α, IL-6) was also significantly suppressed, with Retatrutide showing a 70% reduction, Tirzepatide 50%, and Liraglutide 35%.